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p53 and p19ARF are tumor suppressors frequently
mutated inhuman tumors. In ahigh-throughputscreen
in mice for mutations collaborating with either p53 or
p19ARFdeficiency,we identified10,806 retroviral inser-
tion sites, implicating over 300 loci in tumorigenesis.
This dataset reveals 20 genes that are specifically mu-
tated in either p19ARF-deficient, p53-deficient or wild-
type mice (including Flt3, mmu-mir-106a-363, Smg6,
andCcnd3), aswell as networks of significant collabo-
rative and mutually exclusive interactions between
cancergenes.Furthermore,we foundcandidate tumor
suppressor genes, as well as distinct clusters of inser-
tions within genes like Flt3 and Notch1 that induce
mutants with different spectra of genetic interactions.
CrossspeciescomparativeanalysiswithaCGHdataof
humancancer cell lines revealedknownandcandidate
oncogenes (Mmp13, Slamf6, and Rreb1) and tumor
suppressors (Wwox and Arfrp2). This dataset should
prove to be a rich resource for the study of genetic
interactions that underlie tumorigenesis.
INTRODUCTION
Retroviral insertional mutagenesis in mice has proven to be an
efficient tool for identification of novel cancer genes, providing
a valuable complement to the study of human tumors. Slow
transforming retroviruses, such as Moloney Murine Leukemia
Virus (MuLV), can mutate cellular genes by integration of their
proviruses into the host genome. Cells that have acquired a pro-
liferative advantage through proviral mutation of cellular genes,
may acquire additional mutations by viral reinfection and eventu-
ally develop into tumors (reviewed in Uren et al., 2005). The posi-tion of insertions can be determined by amplifying DNA flanking
the provirus using linker-mediated PCR and mapping the result-
ing sequences onto the genome.Many regions that are tagged in
multiple independent tumors (termed Common Insertion Sites or
Common Integration Sites or CISs) have been identified in previ-
ous studies (compiled in the RTCGD, http://rtcgd.abcc.ncifcrf.
gov/, (Akagi et al., 2004)). A high proportion of these loci are or-
thologous with the loci of known human cancer genes, examples
beingFli-1,Evi1, andPim1 (BenDavid et al., 1988;Morishita et al.,
1988; Cuypers et al., 1984). However, the oncogenic capacity of
many of the candidate cancer genes identified by these screens
still needs further experimental validation.
Components of the p19ARF-MDM2-p53 signaling pathway are
mutated in a large fraction of human cancers (Sharpless, 2005;
Levine et al., 2006). p19ARF acts upstream of p53 and can en-
hance its transcriptional activity by antagonizing MDM2-medi-
ated degradation of p53 (Sherr, 2006). Comutation of p19ARF
and p53 rarely occurs (Eischen et al., 1999; Schmitt et al.,
1999), and deletion of p19ARF in heterozygous p53 knockout
mice reduces the selective pressure for loss of the p53 wild-
type allele for tumor formation (Moore et al., 2003). In addition,
p19ARF was shown to be pivotal for suppression of chemically-
or radiation-induced tumors by p53 in mice (Efeyan et al.,
2006; Christophorou et al., 2006). These data suggest the pri-
mary function of p19ARF is to activate p53. However, several
studies indicate that p19ARF may also suppress tumorigenesis
independently of p53.Mice lacking both p19ARF and p53 showed
tumors in a wider range of tissue types and more frequently de-
veloped multiple primary tumors than mice lacking either of the
two genes (Weber et al., 2000). Furthermore, loss of p19ARF in-
creased the number and size of chemically-induced papillomas
both in wild-type and p53/ mice (Kelly-Spratt et al., 2004).
We performed insertional mutagenesis screens in p53/,
p19ARF/ and wild-type mice to identify genes that collaborate
with loss of either p53 or p19ARF in tumorigenesis and in doing
so gained new insight in the functional differences between theseCell 133, 727–741, May 16, 2008 ª2008 Elsevier Inc. 727
Figure 1. Accelerated Tumor Formation in MuLV-Infected Mice and Identification of Common Insertion Sites Using the GKC Framework
(A) Cumulative survival of p19ARF/, p53/, and wild-type mice infected with MuLV and noninfected p19ARF/ and p53/ mice is plotted against lifespan in
days (p19ARF/ versus wild-type, p value < 0.0001; p53/ versus wild-type, p value < 0.0001, log-rank test).
(B) Flow chart for retrieving retroviral insertions.
(C) Number of CISs varies with kernel size and significance.728 Cell 133, 727–741, May 16, 2008 ª2008 Elsevier Inc.
tumor suppressors. We also used these data to construct net-
works of collaborative and mutually exclusive interactions
betweenCIS loci. To date, the primary limitation of identifying ge-
notype-CIS and CIS-CIS collaborations has been not only the
number of tumors but also the number of inserts per tumor. If
only a fraction of the inserts of each tumor are detected, the
power of any statistical test for genotype specificity or for collab-
oration between loci will be greatly reduced.With this inmind, we
optimized our insertion site cloning and analyzed more than 500
tumors yielding over 10,000 independent insertion sites. By com-
parison, many of the screens published to date identify hundreds
of insertions (Li et al., 1999; Hwang et al., 2002; Lund et al., 2002;
Mikkers et al., 2002; Suzuki et al., 2002; Johansson et al., 2004;
Theodorou et al., 2007; Stewart et al., 2007; Slape et al., 2007),
the largest containing 1538 insertions from 245 tumors (Suzuki
et al., 2006). As a result, a large number of novel CISs were iden-
tified near known and candidate oncogenes and tumor suppres-
sor genes. These data create a resource (http://mutapedia.nki.nl)
that will help cancer researchers to identify new cancer genes




in p19ARF/ and p53/ Mice
We conducted retroviral insertional mutagenesis screens in
p19ARF/, p53/ and wild-type mice on a pure FVB genetic
background. Mice were infected with MuLV at postnatal day 1
and monitored for tumor growth. Both p53/ and p19ARF/
miceare predisposed for development of lymphoma (Donehower
et al., 1992; Kamijo et al., 1999), andMuLV infection further accel-
erated lymphomagenesis in these mice as well as in wild-type
mice (p value < 0.0001 for MuLV-infected p19ARF/ versus non-
infected p19ARF/, p value < 0.0001 for MuLV-infected p53/
versus noninfectedp53/, log-rank test) (Figure 1A).Micedevel-
oped tumors almost exclusively in spleen, thymus and lymph no-
des. The majority of tumors (n = 349) were analyzed by flow cy-
tometry using T cell and B cell-specific markers (CD3 and
B220, respectively, Figure S1A). No large differences were found
in the incidence of tumors in these organs between the different
genotypes, and theproportion of analyzed tumors from thediffer-
ent organs is roughly the same for each genotype (Figure S1B).
High-Throughput Cloning and Sequencing of MuLV
Insertion Sites
To identify genes mutated by proviral insertions, flanking se-
quences of the retroviral insertions were cloned by linker-medi-
ated PCR (Devon et al., 1995; Mikkers et al., 2002) using tumor
DNA digested with either Sau3aI or Tsp509I. For the majority of
samples two PCRs were performed (one for each enzyme) and
shotgun subcloned. 96 colonies per PCR were picked and se-quenced. In total, 510 tumors (220 p19ARF/, 123 p53/, and
167 wild-type), isolated from 455 mice were analyzed, yielding
approximately 100,000 sequence reads. After filtering, 46,197
could be mapped and oriented onto the genome. Sequences
cloned more than once from the same mouse likely represent
the same insertion. Therefore, these were built into contigs to
avoid overcounting the insertions of disseminated tumors. In
total, 10,806 independent insertions were retrieved (3194,
4438, and 3174 from wild-type, p19ARF/ and p53/ tumors,
respectively) (for overview see Figure 1B), yielding an average
of 23.7 insertions per mouse.
Identification of CISs Using a Kernel Convolution-Based
Statistical Framework
To identify common insertion sites (CISs), i.e., regions in the ge-
nome that are significantly more frequentlymutated by insertions
than would be expected by chance, we used a statistical frame-
work based on Gaussian kernel convolution (GKC), which esti-
mates a smoothed density distribution of inserts over the entire
genome (Figure S2A) (de Ridder et al., 2006). Depending on ker-
nel size and p value, the total number of statistically significant
CISs varies (Figure 1C, Table S1). Increasing kernel size may re-
sult in merging independent CISs that may influence the same
gene (as illustrated for the Myc locus in Figure 1D). Smaller ker-
nels sizes may, conversely, reveal separate CISs that affect the
same gene, which may be preferentially mutated in specific
genetic backgrounds or result in expression of different mutant
proteins (see below). Unless stated otherwise a kernel size of
30 kb was used in this paper.
Large-Scale Identification of CISs Near Known and
Unknown Cancer Genes
Applying the GKC framework to the 10,806 insertions from the
p53/, p19ARF/ and wild-type tumors identified 346 CISs
(p value < 0.05) (Figure 1E). By comparison, similar analysis of
the MuLV insertion data present in the RTCGD database identi-
fied 160 CISs from 5435 insertions, 54 of these being shared be-
tween these datasets (Figure S2B). Combined analysis of both
datasets yielded 473 CISs. To select genes that are the most
likely candidate cancer genes, we used the mechanisms of ret-
roviral mutation described by Jonkers and Berns, 1996 (Table
S2). Established proto-oncogenes like Myc, Nmyc1, Ccnd3,
Pim1 and Notch1, rank among the most significant CISs of this
screen (Figure 1E, Table S2). In addition, established cancer
genes like Lmo2, RhoH, Trim33, Mll, and Hspca (Futreal et al.,
2004) are candidate target genes of less frequently mutated
CISs, indicating that lower ranked CISs (carrying 4–5 insertions)
may represent bona fide cancer genes. Importantly, we found
a large number of highly significant CISs near genes that have
not previously been linked to tumorigenesis, including Pik3r5
and Pik3cd, both regulatory subunits of PI3K that upon retroviral
activation may enhance PI3K signaling (Brock et al., 2003),(D) Identification of CISs nearMycwith different kernel sizes. Red line represents insertion density for 300 kb kernel, green line for 30 kb, and the blue line for 5 kb.
Blue and red denote sense and antisense insertions, respectively.
(E) Insertions from p53/, p19ARF/, and wild-type tumors were analyzed together with a 30 kb kernel to determine insertion density over the genome (left
panel). The cut-off (p value < 0.05) for significant insertion density is indicated (red line). CISs (p value < 0.05) are indicated by green vertical bars. A list of the
insertion density of the 15 most significant CISs is included (right panel).Cell 133, 727–741, May 16, 2008 ª2008 Elsevier Inc. 729
miRNA genes like e. g. mmu-mir-24-2/27a/23a and mmu-mir-
142, Lunatic Fringe (Lfng), a modulator of Notch receptor activity
(Haines and Irvine, 2003) and Smg6 (Est1a) which is involved in
nonsense-mediated RNA decay (Fukuhara et al., 2005).
CISs Enriched for Established Cancer Genes
To determinewhat proportion of ourCISs corresponds to verified
human cancer genes, we compared our CISs with lists of known
cancer genes. TheCancerGeneCensus is an actively curated list
of genes the mutation of which contributes to tumor formation
(Futreal et al., 2004). Another list of mutated genes has been de-
rived fromsequencing the coding regions of a panel of breast and
colon tumors (Sjoblom et al., 2006). From these, we composed
a list of 516 unambiguous murine orthologs of human cancer
genes. Depending on window size around the CIS midpoint
(+/50 kb to 300kb),we foundbetween30–79CISs in the vicinity
of murine orthologs of human cancer genes, a highly significant
enrichment compared to an equal number of randomly selected
genes (p valuez0 for all window sizes). This indicates that CISs
are found in the vicinity of cancer genes more frequently than ex-
pected by chance.We then used this overlap as ameasure of the
saturation of our screen i.e., to see how many of these cancer
genes might have been identified using fewer tumors. Subsets
of the total dataset were selected by stepwise addition of ran-
domly selected groups of 50 mice. CISs were then identified for
these random subsets, and we determined the number of known
cancer gene orthologs within 200 kb either side of each CIS mid-
point. The number of cancer genes identified does not reach its
maximum until all the tumors are included (Figure S3), indicating
that significant numbers of known (and by extension unknown)
cancer genes might still be found by performing more extensive
studies with larger amounts of tumors.
Insertions Mutate Pathways Involved in Human Cancer
To identify signaling pathways activated by retroviral insertions,
we took the 346 candidate target genes and used Ingenuity Path-
way Analysis software to investigate whether these genes play
a role in canonical signaling pathways. Our 346 candidate genes
weremost significantly enriched for genes implicated in T cell and
B cell receptor signaling, GM-CSF signaling and IL-2 signaling
(Table S3), which may have been expected since all tumors
wereof lymphoidorigin. Inaddition,wefindsignificantenrichment
formutationof genes involved inERK/MAPK,PI3K/AKTandG1/S
checkpoint regulation. Genes in these pathways are also com-
monly mutated in human cancers, indicating that the signaling
pathways mutated in our screen overlap with signaling pathways
deregulated in human cancer (Table S3, Cancer Gene Census
genes). Selection of the 346 candidate genes may be biased by
manual curation. To rule out possible biases, we also compiled
a list of the nearest gene to the midpoint of each of the 346
CISs. This yielded similar results, demonstrating that these results
are not due to manual curation of CIS candidate target genes.
Identification of Genes Collaborating with
p19ARF or p53 Deficiency
To identify genes that specifically collaborate with deficiency for
either p19ARF or p53, the dataset was analyzed in two ways: (a)
CISsweredeterminedusingall the insertions fromthe threepanels730 Cell 133, 727–741, May 16, 2008 ª2008 Elsevier Inc.Figure 2. Genotype-Specific Distribution of Insertions
(A) Analysis of all panels combined will detect CISs that occur relatively
frequently (peaks B and C) but may not identify CISs in regions that have a
relatively small number of insertions in tumors from the same genotype (peaks
A). Conversely, CISs constituted of a number of insertions from different
panels, may not reach significance when panels are analyzed separately
(peak B).
(B) Schematic overview of genotype-specific CISs found in p19ARF/, p53/,
and wild-type mice. CISs that have a significant bias (p value < 0.05) toward
a particular genotype are depicted. CISs more frequently found in one geno-
type versus another (e.g., Pim2 in p53/ versus p19ARF/) are depicted at
the green end of the wedge pointing toward the other genotype (p19ARF/).
(C) Venn-diagram representing the overlap in numbers of ‘‘individual panel’’
CISs found between genotypes. The number of CISs per genotype is indicated
outside the diagram.
























Ccnd3 17, 45047722 53/19 (0.00003)  59/19 (0.00239)   
Flt3 5, 146256166 10/0 (0.0009)  10/0 (0.0074)   
mmu-mir-106a-363 20, 47271889 35/14 (0.00202)  40/14 (0.02233)   
Runx1 CIS1 16, 91913533 9/0 (0.00185)  14/0 (0.00129)   
Runx1 CIS5 16, 92317511 10/1 (0.00536)     
Gfi1b 2, 28536129 7/0 (0.00665)     
Pim2 20, 6107503  9/2 (0.00868)    
Ssbp3/Thea CIS1 4, 105792860  4/0 (0.02532)    
Rps6kb1 11, 86313637  4/0 (0.02355)    
Chc1l 14, 67474050  4/0 (0.02368)    
Sp1 15, 102462245  4/0 (0.02445)    
Smg6 (Est1a) 11, 74741154   19/3 (0.00882) 19/1 (0.00088)  
Zhfx1a 18, 5356615   14/2 (0.02181)   
Eras/Gata1 20, 6188924   8/0 (0.02518)   
Notch1 CIS2 2, 26433345    13/1 (0.01197)  
Ikaros (Zfpn1a1) 11, 11611278    11/1 (0.02373)  14/1 (0.00095)
Pim1 CIS1 17, 27209067    11/1 (0.02365)  
Notch1 CIS1 2, 26396468     21/11 (0.0053) 21/6 (0.00553)
Gfi1 CIS2 5, 106805956     72/66 (0.01741) 
Ptma 1, 86244930     4/0 (0.02583) 
Phf10/Tcte3 17, 12963705     4/0 (0.02577) 
Contingency tables were used to calculate whether CISs were preferentially mutated in any of the three genotypes compared to the other genotypes.
The number of insertions in the CIS for the respective genotypes is indicated. p values are between brackets.together and CIS-genotype interactions were identified by com-
paring thenumberof insertions inaCIS inonegenotypeversusan-
other, or (b)CISsweredeterminedperpanel, andcandidategenes
of the CISs were compared between panels (see Figure 2A).
Using the first approach (a), with all panels combined, we
found 21 CISs (20 genes) with a significant bias (p < 0.05) toward
one of the genotypes (Figure 2B, Table 1). For example, Runx1,
Ccnd3, the miRNA cluster mmu-mir-106a-363 (encoding mmu-
mir-106a/20b/19b-2/92-2 and 363), Flt3 and Smg6 are preferen-
tially mutated in p19ARF/ tumors compared to wild-type
tumors. Runx1, mmu-mir-106a-363, Ccnd3, and Flt3, but not
Smg6, are also specific for p53/ compared to wild-type, indi-
cating that mutation of these genes is selected for in cells that
lack the p19ARF-p53 tumor suppression pathway. In contrast,
mutation of Smg6 is highly specific for p19ARF/ (p19ARF/
versus wild-type p value = 0.0047, p19ARF/ versus p53/
p value = 0.0003) and may therefore only contribute to tumori-
genesis in a p19ARF-deficient background. P53 can inhibit tumor
development in the absence of p19ARF. We find that Notch1,
which is able to suppress p53 activity through a p19ARF-indepen-
dent, MDM2-dependent pathway (Beverly et al., 2005), is more
frequently mutated in wild-type and p19ARF/ compared to
p53/ (Figure 2B), suggesting that activation of Notch1 in
p19ARF/ and wild-type tumors might be instrumental for sup-
pression of p53 activity. Similar numbers of genes are geno-type-specific for p53/ compared to p19ARF/ and p53/
compared to wild-type. However, genes preferentially mutated
in p53/ versus wild-type collaborate more strongly with p53
deficiency (yield lower p values) than genes preferentially
mutated in p53/ versus p19ARF/.
In our second approach (b), we determined CISs per panel,
thus analyzing insertions that were retrieved from tumors
isolated from mice with the same germ-line genotype. We find
113 CISs in p19ARF/ tumors, 85 in p53/ and 87 in wild-
type tumors. The Venn diagram (Figure 2C) shows that 25 CISs
near frequently mutated genes like Myc, Gfi1, Rasgrp1 and
Rras2 are found in all panels (Figure 2C, Table S4). However,
all panels also have a relatively large number of unique CISs, in-
cluding 17 new CISs that were not found when insertions from
the different panels were analyzed together. Fourteen of these
newly identified loci are exclusively mutated in one of the three
genotypes (Table S4). To determine the activated canonical sig-
naling pathways, we analyzed candidate target genes of CISs
unique for a single genotype (e.g., p19ARF/ but not wild-type
and p53/) with Ingenuity Pathway Analysis. We also analyzed
all CISs that are found in one or two genotypes, but not the third
(e.g., p19ARF/ and/or p53/ but not wild-type). We found that
genes implicated in p53 signaling such asAkt1,Bcl2l1,Gadd45b
andCcnd1 are mutated in wild-type or p19ARF/ tumors but not
in p53/ tumors (Tables S4 and S5). Activation of Akt1 canCell 133, 727–741, May 16, 2008 ª2008 Elsevier Inc. 731
Figure 3. Mapping Interaction Networks between Common Insertion Sites
(A) Co-occurrence between the top 25 300 kbCISs. CIS names andCIS rank are indicated on vertical axis, numbers on horizontal axis are CIS rank. The horizontal
axis represents CISs that are assumed to be the predisposing, more clonal event and the vertical axis represents CISs that are presumed to be subsequent,
subclonal events.
(B) Mutual exclusivity between the top 25 300 kb CISs. Set up of the figure as described in (A).
(C) CIS interaction network representing the co-occurrence or mutual exclusivity of the 20most significant CISs. Co-occurring CISs are connected by green lines
(thin line, 0.001 < p value < 0.05; heavy line, p value < 0.001), mutual exclusive CISs are connected with red lines (thin line, 0.001 < p value < 0.05; heavy line, p
value < 0.001).induce MDM2-mediated degradation of p53 and may thereby
suppress p53-dependent effects on tumor formation (Mayo
and Donner, 2001). Bcl2l1 can inhibit p53-induced apoptosis
(Eischen et al., 2001), whereas Gadd45 has been demonstrated
to have anti-apoptotic activity in hematopoietic cells in response
to genotoxic stress (Gupta et al., 2005). Thus, activation of these
genes in wild-type and p19ARF/ tumorsmay abrogate p53-me-
diated apoptosis and contribute to tumor formation.732 Cell 133, 727–741, May 16, 2008 ª2008 Elsevier Inc.Creating an Interaction Map for All CISs
Previous analyses of insertions in the RTCGD have noted that
some CISs appear to cooperate in oncogenesis (Dave et al.,
2004; de Ridder et al., 2007). We looked for CIS-CIS interactions
by determining whether particular CISs are found mutated to-
gether in the same tumor at higher or lower rates than expected
by chance.We performed analysis of all pairs of CISs, using con-
tingency tables that assume one CIS is the predisposing event,
whereas inserts in the second CIS are assumed to be sub-
sequent events. The reciprocal assumption was also tested.
The set of interactions between all 300 kb CISs is depicted in
Figure S4, with Table S6 ranking themost significant interactions
by p value. Interactions between the top 25 300 kb CISs are de-
picted as a heat map in Figures 3A and 3B and as a network in
Figure 3C. The symmetry observed over the diagonal of these
plots indicates that the contingency table tests yield similar
results regardless of which insert is assumed to have occurred
earlier. Nonetheless, some CIS pairs do break from this trend;
for instance, insertions mutating Notch1 in the presence of an
existing Rai17 insertion (p value = 0.001) appear to be more
strongly selected for than insertions mutating Rai17 in the pres-
ence of an existing Notch1 insertion (0.0356).
Several of these interactions have some precedent within the
literature. For example, Ikaros (Zfpn1a1) and Notch1 insertions
frequently co-occur within the same tumor. Ikaros, a transcrip-
tional regulator of hematopoietic differentiation, is deleted in
acute lymphoblastic leukemia (ALL) (Sun et al., 1999) and has
previously been identified as a CIS in a screen conducted in
transgenic mice expressing the Notch1 intracellular domain
(NotchIC) (Beverly and Capobianco, 2003). Myc and Nmyc1 in-
sertions are mutually exclusive with each other and both loci
are mutually exclusive with Notch1. These three loci may be
functionally redundant because Myc and Nmyc1 are related in
sequence and function, and Notch1 insertions can activate
Myc expression (Sharma et al., 2007).
We also find a rationale within the literature for some of our
novel interactions such as the comutation of Notch1 and Lfng.
Lfng modulates the activity of the Notch1 receptor by glycosyla-
tion and frucosylation of the N-terminal extracellular EGF do-
mains (Stirewalt and Radich, 2003). This suggests that in tumors
where Notch1 is activated Lfng insertions can cooperate to
enhance its activity.
Complete lists of interacting loci for 5 kb, 30 kb and 300 kb
CISs with p values < 0.05 are included (Tables S7, S8, and S6,
respectively). As expected for lower kernel widths, we find
some adjacent CISs that may affect the same gene are mutually
exclusive. For instance, some of the CISs nearMyc using a 5 kb
or 30 kb scale (Figures S5A and S5B) are mutually exclusive
events. This may suggest that once an insert is obtained within
a CIS there is apparently no selection for insertion within an
adjacent CIS affecting the same gene, since this would be a
redundant duplication of the same oncogenic function.
Separate Clusters of Insertions Create Distinct
Flt3 and Notch1 Mutants
Using a kernel width of 5 kb, we found that insertions in fre-
quently mutated genes like Flt3, Notch1, Jundm2 and Ikaros
are unevenly distributed into clusters that may mutate the
same genes by different mechanisms (Figure 4A). Two CISs
were found in or near Flt3, a gene frequently mutated in human
hematopoietic malignancies (Stirewalt and Radich, 2003). One
CIS (CIS25 kb) upstream of the gene has 4 insertions where the
retroviral genome is inserted in the antisense direction relative
to the Flt3 transcript, suggesting that they act by an enhancer
effect on the Flt3 promoter. The other CIS (CIS15 kb) resides in
Flt3 intron 9–10. In tumorswith CIS15 kb insertions, RT-PCR iden-tified chimeric transcripts that fuse the MuLV transcript to Flt3
coding sequences and encode an N-terminally truncated protein
of approximately 65 kDa (Figure 4B and data not shown). West-
ern blot analysis showed high levels of a mutant Flt3 protein of
65kd in tumors having an insertion in Flt3 intron 9-10 but not in
tumors with insertions upstream of Flt3 or normal thymus tissue.
We also found that tumors with insertions upstream of Flt3
(CIS25 kb) are significantly enriched for insertions near Evi1 and
Ets1, but this is not the case for tumors with Flt3 truncating inser-
tions (CIS15 kb) (Figure 4C). Rather, truncated Flt3 is mutually ex-
clusive with mutation of Myc, Gfi1, and Rasgrp1, whereas there
is no selection against mutation of these genes in tumors with
upstream Flt3 insertions.
Similarly, CISs found within and upstream of Notch1 suggest
that Notch1may also give rise to functionally distinct oncogenic
mutants (Figure 4A). CIS45 kb, upstream of Notch1, most likely
enhances Notch1 expression, whereas CIS35 kb in intron 2 may
induce overexpression of full length Notch1 or mutant Notch1
proteins that lack approximately 50 N-terminal amino acids.
The other CISs in Notch1 give rise to a constitutively active
mutant protein consisting of the intracellular domain of Notch1
(NotchIC) (CIS25 kb), or remove the destabilizing COOH-terminal
PEST-domain and thereby increase Notch1 activity (CIS15 kb)
(Hoemann et al., 2000; Weng et al., 2004). Both NotchIC and
Notch1 lacking the PEST-domain closely resemble NOTCH1
mutants found in human cancers (Weng et al., 2004). Interest-
ingly, NotchIC (CIS25 kb) mutations are almost exclusively found
in wild-type tumors (wild-type versus p19ARF/, 11/3, p value =
0.006, wild-type versus p53/, 11/2, p value = 0.011) indicat-
ing that expression of the Notch1IC mutant may be particularly
oncogenic in the wild-type background. Moreover, mutation of
Ikaros is strongly selected for in tumors that have a NotchIC mu-
tation (p = 7.6 3 105) but no significant co-occurrence is found
with other Notch1 mutations. Lastly, in contrast to CIS15 kb and
CIS35 kb, mutations in CIS25 kb (NotchIC) do not co-occur with
Lfng mutations, most likely because NotchIC does not contain
the N-terminal extracellular EGF domains and therefore will not
be activated by increased Lfng levels (Figure 4C). Together,
these data illustrate that increasing the coverage of insertional
mutagenesis screens and analysis with a range of kernel sizes
is informative even for CIS genes that have previously been
established as cancer genes.
Using Intragenic Insertions to Identify Tumor
Suppressor Genes
In some cases, insertions are selected for because they disrupt
and inactivate tumor suppressor genes (Suzuki et al., 2006; re-
viewed in Uren et al., 2005). 4700 of our 10,806 inserts landwithin
the transcribed regions of genes (Table S9). Some of these mu-
tations are within known oncogenes where truncating or en-
hancer mutations within the gene are oncogenic (as previously
discussed for Flt3 and Notch1). However, we also find known
tumor suppressor loci.
The most prevalent known tumor suppressor on this list is
Ikaros (Zfpn1a1), harboring 50 insertions.Another familymember,
Zfpn1a3 (Aiolos), harbors 11 insertions and like Ikaros is also im-
plicated in ALL (Mullighan et al., 2007). Other known tumor
suppressor loci also carry disrupting insertions including NfICell 133, 727–741, May 16, 2008 ª2008 Elsevier Inc. 733
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(20 insertions), Ovca2 (6) and Wwox (7). Candidates of particular
noteare:E2f2 (whichcanactasahaploinsufficient tumor suppres-
sor of Myc-induced lymphoma in mice (Opavsky et al., 2007)),
Raptor (a binding partner and inhibitor ofmTOR (target of rapamy-
cin) (Kimet al., 2002;Hara et al., 2002)),Nfatc3 (found in aprevious
retroviral screen to suppress SL3-3 induced lymphoma (Glud
et al., 2005) and also found to suppress mammary adenocarci-
noma (Leeetal., 2005)),Xrcc6 (Ku70) (knockouts ofwhichdevelop
thymic and disseminated T cell lymphomas [Li et al., 1998]) and
Ablim1, which is located in a chromosomal region frequently lost
in human tumors (Kimetal., 1997)(FigureS6).Notably,weobserve
few inserts within commonly mutated tumor suppressors such as
Cdkn2a, Pten andRb1. These genesmay be poor targets for inte-
gration due to insertion site preferences of the virus or inability of
the virus to inactivate these genes by insertion.
We further postulated that finding multiple intragenic inser-
tions within both alleles of a gene is more likely for tumor sup-
pressor genes than oncogenes. 55 genes carrymore than one in-
tragenic insertion within the same tumor (Table 2). To estimate
the significance of such events, we compared how often genes
were hit twice in real data versus 100,000 permutations of ran-
domized data (shuffling inserts between tumors) and ranked
them by this p value.
Ikaros (Zfpn1a1) is disrupted in 33 tumors, 11 of which carry
more than one intragenic insertion. After shuffling, we find on
average only 3 tumors carrymore than one insertion within Ikaros
(p value = 1 x 105). By comparison, the known oncogene
CyclinD3 (with 148 inserts) is hit more than once in 25 tumors,
however this number is similar to that expected by chance (in
randomized data 22 tumors have more than one hit, yielding
a p value of 0.2). Other known or candidate tumor suppressors
with more hits per tumor than expected are indicated in Table
2, includingMobkl2a (hMOB1),Ablim1,Adrbk1 andNf1 (p values
0.02, 0.03, 0.04, 0.08, respectively). We cannot rule out that there
may be selection for multiple insertions within the same gene in
a single tumor clone even when these insertions are activating
mutations. Nonetheless the most established oncogenes of
this list (AhiI, Evi1, Pim1, Flt3, Gfi1, Evi5, Notch1, and Ccnd3)
are those with higher p values. Thus, it appears that genes with
lower p values in this analysis are better tumor suppressor
candidates than those with higher p values.
Identifying Candidate Cancer Genes by Comparison
of Human Tumor Amplicons and Deletions with Murine
Retroviral Insertions
As part of the Wellcome Trust Sanger Institute’s Cancer Genome
Project, 713humancell lineswerehybridized to10,000probeSNP
arrays and copy number information was extracted from thesedata. Some amplicons and deletions span megabases and
contain many genes, thus making cancer gene identification diffi-
cult. To this end, wemapped our CIS loci to their orthologous loci
in the human genome and looked for overlap with amplicons and
deletions in the tumor cell lines. The human orthologs of our list of
CIS candidate target genes were found to be amplified at a signif-
icantly higher frequency than a random list of genes (p value =
0.03). Significant results were also obtained using the list of
genesnearest to themidpoint of ourCISs (p value=0.006).Known
oncogenes like Fgfr2, Kit and Evi1 and other notable examples
identified in this manner are illustrated in Figure S7 and Figure 5.
A recurrent amplicon on chromosome 6 is orthologous to
a CIS in the vicinity of Rreb1 (Figure 5A). Rreb1 binds and re-
presses expression of the p16(Ink4a) promoter, and the develop-
ment of pristane-induced plasma cell tumors in Balb/C mice is
attributable to a polymorphism in this Rreb1 binding site (Zhang
et al., 2003).
Another amplified region on chromosome 1 contains at least
21 genes, of which Slamf6 appears to be the most likely target
gene of our insertions (Figure 5B). Polymorphisms within the
region of Slamf6 (Ly108) have been implicated in systemic lupus
erythematosus (SLE) (Wandstrat et al., 2004).
A recurrent amplicon on Chromosome 11 contains at least 24
genes, including a cluster of genes encoding matrix metallopro-
teinases (MMPs). Several MMPs within this amplicon have been
previously implicated in cancer, however the only one of these
genes implicated by our insertions is Mmp13, which to date
has not been ascribed a role in cancer (Figure 5C).
We did not see significant global overlap with our lists of tumor
suppressor candidate genes and thedeletionsof thehumanCGH
data. This is perhaps not surprising since,while these listsmaybe
enriched for tumor suppressor genes, they still contain many
oncogenes that have insertions within their transcribed regions.
Nonetheless, we also find candidate tumor suppressor genes
that overlap recurrent deletions.Wwox is disrupted by seven in-
tragenic insertions and deleted within 10 of the human cell lines
(Figure 5D). A novel candidate tumor suppressor emerging from
this comparison is Arfrp2 (Arl15)(Figure 5E). Arfrp2 is a member
of the ADP-ribosylation factor-like family. Notably, anothermem-
ber of this family, ARL11 (ARLTS1), is a tumor suppressor gene
where truncating germline mutations or promoter methylation
contribute to leukemia, breast cancer, ovarian cancer, andmela-
noma (Sych et al., 1978; Frank et al., 2005; Petrocca et al., 2006).
DISCUSSION
Here, we report on a large-scale retroviral insertional mutagene-
sis screen using more than 500 tumors from p19ARF/, p53/Figure 4. Clusters of Insertions within Flt3 and Notch1 Induce Oncogenic Proteins with Distinct Properties
(A) Analysis of Flt3, Notch1, Ikaros and Jundm2with a 5 kb kernel size reveals multiple CISs. Blue bars represent sense insertions, red bars antisense insertions,
green bars introns and black bars exons.
(B) Chimeric transcripts of MuLV and Flt3 sequences are formed by splicing of MuLV splice donor (SD) to splice acceptor of Flt3 exon10 producing a 1682nt
mutant transcript (upper panel), and expression of truncated Flt3 proteins in tumors containing fusion transcripts. Translation starts from an in-frame start codon
in exon10 (lower panel). Protein lysates of tumors with (+) or without () Flt3 insertion were separated with SDS/Page followed by immunoblotting with the in-
dicated antibodies. Tumors with insertions upstream of Flt3 (US).
(C) 300 kb CISs co-occurring ormutually exclusive with the separate 5 kb CISs found inNotch1 and Flt3. 5 kb CIS names are indicated on vertical axis, 300 kb CIS
names on horizontal axis.Cell 133, 727–741, May 16, 2008 ª2008 Elsevier Inc. 735
Table 2. Genes with Multiple Intragenic Insertions
Gene Name (Other Names) # Inserts Total # Tumors Hit Total # Tumors Hit > 1 Expected # Tumors Hit > 1 P Value
Anks1 2 1 1 0 0
Myo1g 2 1 1 0 0
Nr1d1 2 1 1 0 0
Zfpn1a1 (Ikaros) 50 33 11 3.04 1.00E-05
1300010F03Rik 3 2 1 0.01 0.01
2700049A03Rik 3 2 1 0.01 0.01
Smg6 (Est1a) 35 29 5 1.53 0.01
Antxr1 3 2 1 0.01 0.01
Btk 3 2 1 0.01 0.01
Ccr7 13 11 2 0.21 0.01
Cnot2 3 2 1 0.01 0.01
Fgfr1 3 2 1 0.01 0.01
Nedd9 3 2 1 0.01 0.01
Nxf1 3 1 1 0.01 0.01
Rps6kb2 3 2 1 0.01 0.01
Trim30 3 2 1 0.01 0.01
4921504K03Rik’(Iqch) 4 3 1 0.02 0.02
5330417K06Rik’(Mobkl2a/hMOB1) 4 3 1 0.02 0.02
Foxp1 4 3 1 0.02 0.02
Rbm10 4 3 1 0.02 0.02
Ablim1 5 4 1 0.03 0.03
Glb1 5 4 1 0.03 0.03
Sema4b 5 4 1 0.03 0.03
Adrbk1 6 5 1 0.04 0.04
Nfatc1 6 5 1 0.04 0.04
ENSMUSG00000066549 6 5 1 0.04 0.04
ENSMUSG00000068244 6 5 1 0.04 0.04
Prg1 6 5 1 0.04 0.04
Rai17 17 15 2 0.36 0.04
ENSMUSG00000050227 27 24 3 0.92 0.05
Ifi47 7 6 1 0.06 0.06
ENSMUSG00000069613 7 6 1 0.06 0.06
Padi2 7 6 1 0.06 0.06
Rasgrp1 7 6 1 0.06 0.06
Evi2b 8 7 1 0.08 0.07
Runx1 51 45 6 3.17 0.07
Tgtp 8 7 1 0.07 0.07
Bcl2l1 8 6 1 0.08 0.08
Nf1 8 7 1 0.08 0.08
Ubxd5 (Socius/Otud5) 10 9 1 0.12 0.12
Pecam1 10 9 1 0.12 0.12
XP_126601.5 (Slc16a5/MCT6) 11 10 1 0.15 0.14
Zfpn1a3 (Aiolos) 11 10 1 0.15 0.14
DXImx46e 12 11 1 0.18 0.17
Ccnd3 148 112 25 22.05 0.22
Notch1 47 41 4 2.7 0.28
Jundm2 30 27 2 1.13 0.31
Rpl11 17 16 1 0.36 0.31
2610009E16Rik’(Ptms) 17 16 1 0.36 0.32736 Cell 133, 727–741, May 16, 2008 ª2008 Elsevier Inc.
Table 2. Continued
Gene Name (Other Names) # Inserts Total # Tumors Hit Total # Tumors Hit > 1 Expected # Tumors Hit > 1 P Value
Evi5 50 46 4 3.05 0.36
Gfi1 19 18 1 0.46 0.38
Flt3 21 20 1 0.55 0.44
Pim1 21 20 1 0.56 0.44
Evi1 24 23 1 0.72 0.54
Ahi1 31 30 1 1.2 0.73
The p value of genes being mutated by two intragenic insertions in the tumors was estimated by comparison to 100,000 permutations of randomized
data.and wild-type mice. This scale of analysis allows identification of
a high number of new candidate oncogenes and tumor
suppressors and detects highly significant combinations of
co-occurring or mutually exclusive genes. Notably, a significant
proportion of CISs that map to orthologs of known human cancer
loci are not only identified in hematopoietic tumors, but also in
other tumor types such as lung, colon, breast, and prostate
tumors.
We have identified 25 CISs that were significantly more mu-
tated in one of the germline genotypes compared to either one
or both of the two other genotypes. Together with p53 and
RAS, FLT3 is the most commonly mutated gene in human
AML, occurring in approximately 25% of cases (Stirewalt and
Radich, 2003). Flt3 is almost exclusively mutated in p53/ and
p19ARF/ tumors and not in wild-type tumors (11, 13 and 2 in-
sertions, respectively), indicating that Flt3mutationsmay be par-
ticularly oncogenic in the absence of a functional p19ARF-MDM2-
p53 pathway. Flt3 induces Ras signaling (Stirewalt and Radich,
2003), and mutation of Flt3 is mutually exclusive with Ras muta-
tions in human cancers suggesting that mutation of Flt3 has sim-
ilar effects as Ras mutation (Stirewalt et al., 2001). We find that
mutations in the Ras-activating Rasgrp1 (Ebinu et al., 2000) are
mutually exclusive with mutation of Flt3, also suggesting that ac-
tivation of Ras signaling may be an important effect of Flt3muta-
tion in tumors.
The utility of retroviral insertions is further illustrated by com-
parison to array CGHdata from cancer cell lines.We identify sev-
eral novel candidate cancer genes including Rreb1,Mmp13 and
Arfrp2 (Arl15). Similarly useful comparisons can also be envis-
aged for tumor resequencing data. Human populations carry
many polymorphisms, only some of which contribute to tumor
susceptibility and many tumors have a mutator phenotype that
creates a background of irrelevant mutations. In such studies
polymorphisms and background mutations can only be distin-
guished from oncogenic mutations by stringent statistics that
may inadvertently exclude rare but genuine oncogenic events.
CIS loci should be a useful tool to help focus future resequencing
studies, as illustrated by a recent study which finds overlap
between mutations in coding regions of human breast cancer
genes and CIS loci from anMMTV insertional mutagenesis study
(Theodorou et al., 2007; Wood et al., 2007). As such, CIS asso-
ciations could be used to prioritize which rarely mutated genes
should be sequenced within a tumor set i.e., identifying the com-
monly mutated genes in a set of tumors and then sequencing
their known collaborators from insertional mutagenesis screens.Due to the tropism of MuLV, our screen is limited in its ability to
identify cancer genes from nonhematopoietic tumors. As the
technology of transposon mutagenesis matures a greater range
of tumor types will become amenable to analysis by insertional
mutagenesis. New models notwithstanding, there is still much
tobegained from traditionalMuLVscreens. Larger numbersof in-
serts and better estimates of tumor clonality will improve the
power of association studies, giving rise to interaction maps
that are denser andmore informative. Even if complete saturating
coverage of each tumor is possible, it remains unclear howmany
more loci might be identified by increasing the number of tumors
analyzed. Certainly it appears that screening a greater variety of
genotypes and predisposing mutations will expand the range of
mutations found. Also, given the differences in susceptibility for
tumor development between different inbred mouse strains, it
would be interesting to compare the spectrum of oncogenic
mutations between these strains. Analysis of MuLV tumors by
expression arrays and by linker-mediated PCR on cDNA of all
tumors will increase the accuracy with which target genes of
insertions can be identified. CGH copy number arrays and ORF
resequencing might also identify cooperating mutations that
are less amenable to mutation by insertion.
Ultimately there may also be clinical applications of mutually
exclusive interactions of CIS loci. Recent studies have indicated
that EGFR mutations are mutually exclusive with KRAS muta-
tions in lung adenocarcinomas (Pao et al., 2005). Mutant EGFR
is a target for gefitinib and erlotinib, and patients with mutations
in KRAS instead of EGFR do not see any benefit from the use of
these drugs. In cases where the target of a drug is unknown or
unclear, knowing the associations of nontarget mutations that
correlate with treatment outcomes can inform the search for
the actual target and/or suggest novel indications for established
therapies.
EXPERIMENTAL PROCEDURES
MuLV Infection of p19ARF/, p53/, and Wild-Type Mice
Crosses between F0 parental FVB mice +/ for the p19ARF knockout allele
(Kamijo et al., 1997) were performed to generate F1 p19ARF/, p19ARF+/
and p19ARF+/+ (wild-type) offspring. F0 parental FVB mice+/ for the p53
knockout allele (Donehower et al., 1992) were crossed to generate p53/,
p53+/ and p53+/+ F1 offspring. Newborn F1 pups were injected i.p. with
1.105 infectious units of MuLV. Animals were monitored in time for the devel-
opment of tumors, moribund mice were sacrificed and tumors were isolated.
All animal experiments were done conform national regulatory standards
approved by the DEC (Animal Experiments Committee).Cell 133, 727–741, May 16, 2008 ª2008 Elsevier Inc. 737
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Identification of Retroviral Insertion Sites
Genomic DNA was isolated using PureGene from Gentra Systems, Inc. Inser-
tions sites were identified using an linker-mediated PCR protocol adapted
from Mikkers et al. (Mikkers et al., 2002). PCR products were shotgun subcl-
oned using a protocol developed at the Wellcome Trust Sanger Institute
(both protocols available on http://mutapedia.nki.nl/).
Mapping of Insertions
Detailed instructions and parameters used for informatics are available on re-
quest. Briefly, we used cross_match (Dr. Philip Green, unpublished data) to
identify vector, primer, linker and viral U5 LTR sequences in the reads. We
used SSAHA2 (Ning et al., 2001) to map individual reads onto the mouse ge-
nome (NIH Build 34). Chimeric and concatameric subcloning products were
separated where possible or else discarded. Sequences containing a splinker-
ette but lacking an LTR were discarded, unless they were within 2000 bp of
contigs that containing an LTR-genome junction, in which case they were
added to these contigs where orientation was consistent. A final round of filter-
ing to remove PCR artifacts was then applied.
Software
Pathway analysis was performed using Ingenuity Pathway Analysis software
(Ingenuity Systems, www.ingenuity.com). Cytoscape software (version
2.4.0, www.cytoscape.org) was used to create the CIS interaction network.
Identification of CISs Near Orthologs of Human Cancer Genes
Each of the 30 kb CISs was examined for the presence of a murine ortholog of
a human cancer gene within 200 kb up and downstream of the CIS peak. The
number of unique orthologs was counted. Next, the number of insertions in the
dataset was decreased step-wise to zero by removing insertions from 50 ran-
domly selected mice. CIS positions are determined each time 50 mice are
taken out of the dataset, as well as the number of unique orthologs. The exper-
iment was repeated 20 times, average and standard deviation of the number of
murine orthologs was determined. To reduce computation time required for
the saturation analysis, CISs were determined using an alternative method
that applies amore stringent a-level then GKC to determine CISs and therefore
detects less CISs.
Statistical Methods
Significance of genotype-CIS interactions and CIS-CIS interactions were esti-
mated by permutation. Briefly, inserts were placed within a 23 2 contingency
table based on whether the insert is found within a given CIS and either the ge-
notype of themouse or the presence or absence of insertions from another CIS
within the same mouse. Similar tables were constructed for 100,000 random
permutations of data where the entire set of insertions was shuffled between
all tumors. A Chi squared test statistic was calculated for each of the real
and permuted tables. p values were calculated as the proportion of permuted
test statistics that are greater than the real test statistic.
CGH Comparison
Weobtained 10K SNP array CGH data for 713 human cancer cell lines from the
Wellcome Trust Sanger Institute (ftp://ftp.sanger.ac.uk/pub/cgp/10kdata). We
identified regions of copy number change in each cell line and identified human
orthologs of mouse CIS candidate genes overlapping with amplicons and
deletions in the human cancer cell lines. For further details see Supplemental
Experimental Procedures.Transfection and Plasmids
Phoenix cells were transfected using CaPO4 precipitation. The LXSN-Flt3 vec-
tor used as a positive control for Flt3 expression was obtained from Dr. Olivier
Rosnet, Inserm, Marseille, France.
Protein Extraction and Western Blotting
Protein was isolated from frozen tumormaterial or Phoenix cells and loaded on
SDS-PAGE gels. Antibodies used are Flt3 (8F2) (Cell Signaling Technology,
Inc) and alpha tubulin (Sigma-Aldrich, Inc). A protein lysate from a thymus iso-
lated from a 40-day-old wild-type mouse was used as control.
SUPPLEMENTAL DATA
Supplemental Data include seven figures and nine tables and can be found
with this article online at http://www.cell.com/cgi/content/full/133/4/727/
DC1/.
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